FOS and myeloid sarcoma: These analyses validated our previous epigenomic observations and revealed the significant enrichment of AP‐1 members (FOSL1–FOSL2) and RUNX factors (RUNX1–RUNX2), both of which were more evident in the context of the MS phenotype (Fig. 4D).